We recently traveled to Columbus, Ohio for a State of the Science Summit on Ovarian Cancer. At the meeting, faculty from The Ohio University Comprehensive Cancer Center–James, discussed the importance of performing genetic testing upon diagnosis, shared insight on the evolution of ovarian cancer therapeutics, and provided perspective on individualized approaches in the frontline setting.

Additionally, panelists highlighted selection criteria for surgical procedures in ovarian cancer, contextualized the role of secondary surgery in the recurrent setting, and shed light on real-world evidence with PARP inhibitors in this space.

We recently traveled to Chicago, Illinois, for a State of the Science Summit™ on Lung Cancer. Jyoti D. Patel, MD, and Lawrence E. Feldman, MD, discuss second-line therapy in extensive-stage small cell lung cancer and the need for consolidative radiation, as well as the optimal sequence of therapy for a patient with non–small cell lung cancer who harbors a MET exon 14 mutation.

We had the pleasure of sitting down with Guru P. Sonpavde, MD, the director of the Bladder Cancer Program and a physician at Dana-Farber Cancer Institute.

In our exclusive interview, Dr. Sonpavde discusses how the COVID-19 pandemic has impacted treatment decisions for patients with bladder cancer, specifically, as they relate to the dosing and scheduling of chemotherapy, immunotherapy, and targeted therapy.

Moreover, Dr. Sonpavde sheds light on chemotherapy concerns for patients with muscle invasive and metastatic bladder cancer, perioperative surgical concerns for those at risk of COVID-19, and the preventative measures Dana-Farber Cancer Institute has put into place to reduce the risk of patients and providers contracting the virus.

In this special edition of OncLive On Air, we collaborated with one of our sister brands, CURE, for an exclusive interview with Ruben Mesa, MD and his patient, Antje Hjerpe, who has been living with essential thrombocythemia for 35 years, to discuss Hjerpe's treatment course, the current state of treatment in ET and ongoing research efforts, and resources to educate physicians and patients on MPNs.

We recently traveled to Chicago, Illinois for a State of the Science Summit™ on Hematologic Malignancies. At the meeting, faculty from Rush University Medical Center shed light on ongoing research that is poised to add new options to the armamentarium in myelofibrosis, highlighted the novel agents that have strengthened treatment options in non-Hodgkin lymphoma, and discussed treatment considerations for patients with Hodgkin lymphoma. Moreover, faculty shared insights on the novels agents and combinations that have transformed the multiple myeloma treatment paradigm and provided perspective on ongoing research with blinatumomab and CAR T-cell therapy in new settings in acute lymphoblastic leukemia.

We recently traveled to Nashville, Tennessee for a State of the Science Summit™ on Genitourinary Malignancies. At the meeting, faculty from Vanderbilt-Ingram Cancer Center shared insight on recent developments in prostate cancer. Specifically, panelists discussed selection criteria for androgen receptor-directed agents in nonmetastatic castration-resistant prostate cancer and explained how a population-based study has the potential to inform decision making in localized prostate cancer.

Moreover, faculty assessed some of the long-anticipated treatment advances made in metastatic urothelial cancer and discussed the breadth of therapeutic options available in renal cell carcinoma, as well as the patient factors that are used to inform treatment selection.

We had the pleasure of speaking with Jaffer Ajani, MD, who discussed some of the investigational HER2-targeted treatment strategies with trastuzumab, antibody-drug conjugates, and bispecific antibodies that are under investigation in gastrointestinal malignancies. Listen on to hear Ajani discuss some of the HER2-targeted strategies that are under exploration in gastric/GEJ cancer and colorectal cancer, the potential downsides of bulk tumor testing, and the promise of liquid biopsies in the space.

We had the pleasure of speaking with Ian Chau, MD, FRCP, who discussed the state of HER2-directed therapy in gastric/gastroesophageal cancer. Listen on to hear Chau discuss HER2 testing in gastric/GEJ cancer and several HER2-targeted strategies under evaluation.

We had the pleasure of speaking with John L. Marshall, MD, who discussed the evolving treatment landscape of HER2-targeted treatment strategies in colorectal cancer. Listen on to hear Marshall discuss the necessity of identifying patients with HER2-positive colorectal cancer and the work being done to better elucidate effective targeted treatments for patients.

We had the pleasure of speaking with Ryan Corcoran, MD, PhD, who discussed key takeaways regarding the use and investigation of HER2-targeted therapies in gastrointestinal malignancies. Listen on to hear Corcoran discuss the current testing standards and practice patterns surrounding the treatment of HER2-positive gastrointestinal malignancies and provide insight on the current understanding of acquired resistance to HER2-directed therapy.